Charles River Labs Intl Aktie
200,70 €
Deine Einschätzung
Charles River Labs Intl Aktie
Was spricht für und gegen Charles River Labs Intl in den nächsten Jahren?
Pro
Kontra
Rendite von Charles River Labs Intl im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Charles River Labs Intl | 0,65 % | 1,26 % | 1,41 % | 8,19 % | -5,77 % | -38,81 % | - |
Ironwood Pharmaceuticals | -3,25 % | 0,00 % | 6,25 % | -37,70 % | -41,67 % | -46,40 % | - |
Arrowhead Pharmaceuticals Inc. | 0,55 % | 0,89 % | 9,05 % | -19,77 % | -7,60 % | -54,89 % | -2,91 % |
Novocure Ltd | -1,56 % | 2,55 % | -5,27 % | -51,64 % | 18,46 % | -89,48 % | - |
Kommentare
News
![Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=de)
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled
![Charles River to Perform Plasmid Manufacturing for AAVantgarde: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=de)
Charles River to Perform Plasmid Manufacturing for AAVantgarde
Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing
![Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=de)
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and